- Home
- / ASLAN Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
ASLAN Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Total Funding
$100 M
Revenue
$12 M
FY, 2023
CreditSafe Score
?
Score changed on Jun 03, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| TWD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|
| Revenue | 92.4M | 12.0M | ||||
| Cost of goods sold | 12.5M | |||||
| Gross profit | 5.6M | 79.8M | 12.0M | |||
| Gross profit margin, % | 100.0% | |||||
| Operating expense total | 1.3B | 760.5M | 16.2M | 33.6M | 47.6M | 55.4M |
| Depreciation and amortization | 7.3M | 725.5M | 298.0K | 283.0K | 332.0K | 348.0K |
| EBITDA | (1.3B) | (680.7M) | (16.2M) | (34.0M) | (48.0M) | (43.4M) |
| EBITDA margin, % | -361.6% | |||||
| EBIT | (1.3B) | (1.4B) | (15.7M) | (29.7M) | (48.0M) | (39.8M) |
| EBIT margin, % | -331.9% | |||||
| Interest income | 8.1M | 4.6M | 1.0K | 449.0K | 405.0K | |
| Interest expense | 14.8M | 27.8M | 1.2M | 1.9M | 3.7M | 4.3M |
| Pre tax profit | (1.3B) | (1.4B) | (17.0M) | (31.6M) | (51.3M) | (44.1M) |
| Income tax expense | 435.0K | 12.6M | 99.0K | 133.0K | ||
| Net Income | (1.3B) | (1.5B) | (17.0M) | (31.6M) | (51.4M) | (44.2M) |